Zoledronic Acid Boosts Survival in Lung Cancer Patients With High N-telopeptide Levels: Presented at ECCO
Zoledronic acid treatment appears to improve survival in patients with non-small cell lung cancer (NSCLC) and high levels of N-telopeptide, according to data reported here at the 14th European Cancer Conference (ECCO).
This entry was posted on Monday, September 24th, 2007 at 2:08 pm and is filed under Research, Non-Small-Cell, Treatment. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.